Ampio Pharmaceuticals, Inc. (AMPE) Financial Statements (2024 and earlier)

Company Profile

Business Address 9800 MOUNT PYRAMID COURT, SUITE 400
ENGLEWOOD, CO 80112
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,953,00010,352,00012,653,00016,947,00022,890,00028,837,000
Cash and cash equivalents6,953,00010,352,00012,653,00016,947,00022,890,00028,837,000
Receivables      19,000
Prepaid expense1,418,00054,00013,00070,000112,000124,000
Deferred costs      
Other undisclosed current assets778,000329,000663,0001,304,0001,642,000927,000
Total current assets:9,149,00010,735,00013,329,00018,321,00024,644,00029,907,000
Noncurrent Assets
Operating lease, right-of-use asset   75,000150,000525,000577,000
Property, plant and equipment   184,000367,0002,046,0002,302,000
Total noncurrent assets:   259,000517,0002,571,0002,879,000
TOTAL ASSETS:9,149,00010,735,00013,588,00018,838,00027,215,00032,786,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,141,0002,325,000852,0003,592,0004,757,0005,208,000
Employee-related liabilities11,000292,000
Accounts payable627,000575,00097,000218,000718,0001,582,000
Accrued liabilities688,0001,565,000334,000748,0001,110,000415,000
Other undisclosed accounts payable and accrued liabilities826,000185,000421,0002,626,0002,918,0002,919,000
Other undisclosed current liabilities354,000347,000340,000332,000325,000318,000
Total current liabilities:2,495,0002,672,0001,192,0003,924,0005,082,0005,526,000
Noncurrent Liabilities
Long-term debt and lease obligation:    362,000448,000533,000
Liabilities, other than long-term debt 94,000185,000607,000703,0001,588,0004,474,000
Asset retirement obligations   289,000282,000  
Operating lease, liability 94,000185,000274,000362,000448,000533,000
Derivative instruments and hedges, liabilities   44,000421,0001,588,0004,474,000
Total noncurrent liabilities: 94,000185,000607,0001,065,0002,036,0005,007,000
Total liabilities:2,589,0002,857,0001,799,0004,989,0007,118,00010,533,000
Equity
Equity, attributable to parent6,560,0007,878,00011,789,00013,849,00020,097,00022,253,000
Common stock 2,0002,0002,0002,00023,00023,000
Additional paid in capital245,802,000245,749,000245,726,000245,566,000245,382,000245,468,000
Accumulated deficit(239,244,000)(237,873,000)(233,939,000)(231,719,000)(225,308,000)(223,238,000)
Total equity:6,560,0007,878,00011,789,00013,849,00020,097,00022,253,000
TOTAL LIABILITIES AND EQUITY:9,149,00010,735,00013,588,00018,838,00027,215,00032,786,000

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Operating expenses(1,560,000)(4,399,000)(2,701,000)(7,658,000)(4,988,000)(6,970,000)
Operating loss:(1,560,000)(4,399,000)(2,701,000)(7,658,000)(4,988,000)(6,970,000)
Nonoperating income189,000421,000481,0001,247,0002,918,0001,334,000
Investment income, nonoperating91,00030,000377,0001,167,0002,886,0001,331,000
Loss from continuing operations:(1,371,000)(3,978,000)(2,220,000)(6,411,000)(2,070,000)(5,636,000)
Loss before gain (loss) on sale of properties:(6,411,000)(2,070,000)(5,636,000)
Net loss attributable to parent:(1,371,000)(3,978,000)(2,220,000)(6,411,000)(2,070,000)(5,636,000)
Other undisclosed net loss available to common stockholders, basic   (377,000)(1,167,000)(2,886,000)(1,331,000)
Net loss available to common stockholders, diluted:(1,371,000)(3,978,000)(2,597,000)(7,578,000)(4,956,000)(6,967,000)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(1,371,000)(3,978,000)(2,220,000)(6,411,000)(2,070,000)(5,636,000)
Comprehensive loss, net of tax, attributable to parent:(1,371,000)(3,978,000)(2,220,000)(6,411,000)(2,070,000)(5,636,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: